Reach Us +1-217-403-9671
An Efficient Kinase Assay And A Rapid Screening Of Kinase Inhibitors Based On A Biochip | 8227
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

An efficient kinase assay and a rapid screening of kinase inhibitors based on a biochip

2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

Sang Hyun Park, Mi Hee Choi, Jung Ae Kang, and Jong Kook Rho

ScientificTracks Abstracts: JBB

DOI: 10.4172/2153-2435.10000S4

T he major issue with biosimilars in the United States market is uncertainty. Th ere are more questions than answers but the answers to these questions will have a tremendous impact on how the market for biosimilars will develop not only in the United States but also globally. Currently the United States is developing a pathway for the introduction of biosimilars. Th e U.S. Food and Drug Administration has the charge of developing this pathway. Among the many issues the FDA faces in determining this pathway are safety, effi cacy and even what constitutes a biosimilar. How the FDA establishes the pathway will have a tremendous infl uence on the competitive impact of biosimilars in the market. Other factors that the FDA must take into account are clinical trials, interchangeability and immunogenicity. Also, aff ecting the market are data exclusivity, patent protection and insurance reimbursement especially Medicare. Competition from biosimilars in the European Union has decreased price by only around 20 percent which is considerably diff erent from the 80 to 90 percent decrease in price in the chemical generic market. Also, at issue is whether entry will occur through a Biologics License Application (BLA) and not through an abbreviated BLA. Th e impact of biosimilars on the incentive to innovate and the potential decrease in the development of new life saving biologics will be discussed. We analyze the potential impact of biosimilars taking into account these various issues.
Joseph P. Fuhr Jr. is a professor of economics at Widener University. He received his Ph.D. in economics from Temple University. Dr. Fuhr is a healthcare economist and has published over 50 academic articles. He has published and presented on biosimilars as well as pharmacoeconomic studies on cost bene fi t analysis. Dr. Fuhr is a member of the editorial board of Pharmaceutica Analytica Acta